Innovation in Botulinum Toxins
Authors:
- 19 October 2024
- journal article
- research article
- Published by Elsevier in Dermatologic Clinics
- Vol. 43 (1) , 55-66
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Treatment of Moderate-to-Severe Glabellar Lines With RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results From the READY-1 Phase 3 TrialToxicon, 2024
- Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled TrialsAesthetic Plastic Surgery, 2022
- Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar LinesAesthetic Surgery Journal, 2022
- Important Considerations in the High-Dose Toxins DiscussionAesthetic Surgery Journal Open Forum, 2022
- Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type ADrugs, 2021
- High-Dose Neuromodulators: A Roundtable on Making Sense of the Data in Real-World Clinical PracticeAesthetic Surgery Journal Open Forum, 2021
- Safety, pharmacodynamic response, and treatment satisfaction with onabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate-to-severe dynamic glabellar linesToxicon, 2021
- A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 StudyDermatologic Surgery, 2020
- Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III StudiesDermatologic Surgery, 2019
- Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar LinesAesthetic Surgery Journal, 2019